NAUT Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

2.705

Open

2.530

VWAP

2.51

Vol

208.17K

Mkt Cap

307.55M

Low

2.400

Amount

522.85K

EV/EBITDA(TTM)

--

Total Shares

126.56M

EV

214.27M

EV/OCF(TTM)

--

P/S(TTM)

--

Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.

Show More

Events Timeline

(ET)

2026-03-02

08:30:00

Nautilus Biotechnology Appoints Amber Faust as VP of Sales

2026-02-26 (ET)

2026-02-26

08:10:00

Nautilus Biotechnology CEO Highlights Path to Commercialization by 2026

2026-02-24 (ET)

2026-02-24

08:20:00

Nautilus Biotechnology Launches Voyager Platform

2026-01-28 (ET)

2026-01-28

08:20:00

Nautilus Collaborates with Michael J. Fox Foundation to Study Parkinson's Disease

2026-01-08 (ET)

2026-01-08

08:50:00

Nautilus Biotechnology Launches Early Access Program with Tau Proteoforms Assay

2025-11-03 (ET)

2025-11-03

08:13:39

Nautilus reveals the setup and testing of its external field evaluation unit.

2025-10-28 (ET)

2025-10-28

08:04:57

Nautilus Biotechnology announces Q3 EPS of 11 cents, compared to a loss of 13 cents last year.

News

seekingalpha

02-26seekingalpha

Nautilus Biotechnology Q4 2025 Earnings Call Highlights

seekingalpha

02-26seekingalpha

Nautilus Biotechnology Reports Q4 Earnings and 2026 Outlook

Yahoo Finance

02-22Yahoo Finance

BETA Technologies Upgraded to Buy by Jefferies Amid Potential Catalysts

NASDAQ.COM

2025-10-28NASDAQ.COM

Nautilus (NAUT) Third Quarter 2025 Earnings Call Summary

NASDAQ.COM

2025-10-23NASDAQ.COM

VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements

NASDAQ.COM

2025-09-11NASDAQ.COM

Biotech Stocks Surge After Hours: Insider Purchases, Trial Progress, and Strategic Partnerships Drive Growth

2 Analyst Rating

Wall Street analysts forecast NAUT stock price to rise

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

2.50

Averages

2.50

High

2.50

Current: 0.000

Low

2.50

Averages

2.50

High

2.50

Guggenheim

Buy

maintain

$4

AI Analysis

2026-02-27

Reason

Guggenheim

Price Target

$4

AI Analysis

2026-02-27

maintain

Buy

Reason

Guggenheim raised the firm's price target on Nautilus Biotechnology to $4 from $2.50 and keeps a Buy rating on the shares. Every aspect of the Q4 report firms up Nautilus' foundation, showing line of sight to revenue, "albeit modest," this year and in 2027, the analyst tells investors in a post-earnings note.

Valuation Metrics

The current forward P/E ratio for Nautilus Biotechnology Inc (NAUT.O) is -3.16, compared to its 5-year average forward P/E of -5.91. For a more detailed relative valuation and DCF analysis to assess Nautilus Biotechnology Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-5.91

Current PE

-3.16

Overvalued PE

-0.02

Undervalued PE

-11.81

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-2.65

Current EV/EBITDA

-1.86

Overvalued EV/EBITDA

1.26

Undervalued EV/EBITDA

-6.56

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

546.00

Current PS

0.00

Overvalued PS

1700.88

Undervalued PS

-608.88

Financials

AI Analysis

Annual

Quarterly

Whales Holding NAUT

Cercano Management LLC

Amazon.com, Inc.

Comprehensive Financial Management LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Nautilus Biotechnology Inc (NAUT) stock price today?

The current price of NAUT is 2.43 USD — it has decreased -3.19

What is Nautilus Biotechnology Inc (NAUT)'s business?

Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.

What is the price predicton of NAUT Stock?

Wall Street analysts forecast NAUT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NAUT is2.50 USD with a low forecast of 2.50 USD and a high forecast of 2.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Nautilus Biotechnology Inc (NAUT)'s revenue for the last quarter?

Nautilus Biotechnology Inc revenue for the last quarter amounts to -15.42M USD, decreased -22.80

What is Nautilus Biotechnology Inc (NAUT)'s earnings per share (EPS) for the last quarter?

Nautilus Biotechnology Inc. EPS for the last quarter amounts to -12619000.00 USD, decreased -13.35

How many employees does Nautilus Biotechnology Inc (NAUT). have?

Nautilus Biotechnology Inc (NAUT) has 130 emplpoyees as of March 11 2026.

What is Nautilus Biotechnology Inc (NAUT) market cap?

Today NAUT has the market capitalization of 307.55M USD.